This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1979 Dec;6(4):239-49.

doi: 10.1016/s0305-7372(79)80040-7.

Zinostatin (neocarzinostatin)

B F Issell, A W Prestayko, R L Comis, S T Crooke

PMID: 161199
DOI: 10.1016/s0305-7372(79)80040-7

Review

Zinostatin (neocarzinostatin)

B F Issell et al. Cancer Treat Rev. 1979 Dec.

. 1979 Dec;6(4):239-49.

doi: 10.1016/s0305-7372(79)80040-7.

Authors

B F Issell, A W Prestayko, R L Comis, S T Crooke

PMID: 161199
DOI: 10.1016/s0305-7372(79)80040-7

No abstract available

PubMed Disclaimer

Similar articles

Mode of decrease of leukemic cells and leukocytes during neocarzinostatin treatment.
Masaoka T, Hasegawa Y, Yoshitake J, Ueda T, Takubo T. Masaoka T, et al. Cancer Treat Rep. 1977 Jan-Feb;61(1):73-5. Cancer Treat Rep. 1977. PMID: 140763 Clinical Trial. No abstract available.
Neocarzinostatin: a new agent active in the treatment of acute leukemia.
Kitajima K, Kamimura O, Nagao T, Takahashi I, Hiraki K. Kitajima K, et al. Bibl Haematol. 1975;(40):751-2. doi: 10.1159/000397597. Bibl Haematol. 1975. PMID: 126059 No abstract available.
Neocarzinostatin in cancer chemotherapy (review).
Maeda H. Maeda H. Anticancer Res. 1981;1(3):175-86. Anticancer Res. 1981. PMID: 6211130 Review.
Clinical investigations of neocarzinostatin in Japan.
Kimura I. Kimura I. Recent Results Cancer Res. 1978;63:252-60. doi: 10.1007/978-3-642-81219-4_24. Recent Results Cancer Res. 1978. PMID: 151899 Review.
Phase I study of neocarzinostatin in patients with acute leukemia.
Van Echo DA, Wiernik PH. Van Echo DA, et al. Cancer Treat Rep. 1978 Sep;62(9):1363-5. Cancer Treat Rep. 1978. PMID: 150945 Clinical Trial. No abstract available.

See all similar articles

Cited by

Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53.
Senturk JC, Bohlman S, Manfredi JJ. Senturk JC, et al. Oncogene. 2017 Nov 2;36(44):6085-6096. doi: 10.1038/onc.2017.229. Epub 2017 Jul 10. Oncogene. 2017. PMID: 28692049 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database